Large Molecule Patents
Stelara is a drug owned by Janssen Biotech, Inc.. It is protect by 6 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10961307 | JANSSEN BIOTECH, INC. | Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody |
Sep, 2039
(14 years from now) | Active |
| US9217168 | JANSSEN BIOTECH, INC. | Methods of cell culture |
Mar, 2033
(8 years from now) | Active |
| US9663810 | JANSSEN BIOTECH, INC. | Methods of cell culture |
Mar, 2033
(8 years from now) | Active |
| US8852889 | JANSSEN BIOTECH, INC. | Cell culture process |
Jul, 2032
(7 years from now) | Active |
| US9475858 | JANSSEN BIOTECH, INC. | Cell culture process |
Jul, 2032
(7 years from now) | Active |
| US6902734 | JANSSEN BIOTECH, INC. | Anti-IL-12 antibodies and compositions thereof |
Sep, 2023
(1 year, 2 months ago) |
Expired |
Stelara's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
About Stelara
Active Ingredients:
Stelara contains Ustekinumab as an active ingredient
Approval Date:
Stelara was first approved for market use on 23 Sep, 2016.
Dosage:
Stelara is available in 1 strengths and the following dosage forms are - Injection form for Intravenous use, Injection form for Intravenous use.
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 130MG/26ML (5MG/ML) | Injection | Rx | Intravenous |
| 130MG/26ML (5MG/ML) | Injection | Rx | Intravenous |
| 130MG/26ML (5MG/ML) | Injection | Rx | Intravenous |